14088-94-9

Usage

Uses

Used in the Chemical Industry:
1-(3-methylphenyl)-2-imidazolidinone is used as a solvent in the chemical industry for its high solvency power and low evaporation rate, which contribute to its stability and effectiveness in various applications.
Used in the Ink Industry:
In the ink industry, 1-(3-methylphenyl)-2-imidazolidinone is used as a solvent due to its ability to dissolve a wide range of substances, ensuring consistent ink performance and quality.
Used in the Polymer Industry:
1-(3-methylphenyl)-2-imidazolidinone is utilized as a solvent in the polymer industry to facilitate the processing and manufacturing of polymers, enhancing their properties and workability.
Used in the Resin and Coatings Industry:
1-(3-methylphenyl)-2-imidazolidinone is also used as a solvent in the production of resins and coatings, where its solvency and stability are crucial for achieving desired product characteristics and performance.
Used in Organic Synthesis and Pharmaceutical Manufacturing:
1-(3-methylphenyl)-2-imidazolidinone serves as a reagent in organic synthesis and pharmaceutical manufacturing processes, where its unique properties are harnessed to produce a variety of chemical products and pharmaceuticals.

Upstream product

• 497-25-6 dimethylenecyclourethane 
• 621-29-4 3-tolyl isocyanate 
• 120-93-4 imidazolidone 
• 625-95-6 3-Iodotoluene 
• 15145-36-5 1-(2-chloro-ethyl)-3-m-tolyl-urea 
• 99516-18-4 N-m-tolyl-ethylenediamine; hydrochloride 
• 530-62-1 1,1'-carbonyldiimidazole 
• 108-44-1 1-amino-3-methylbenzene 

Downstream Products

• 1225208-16-1 C₁₈H₂₇N₃O 

Relevant academic research and scientific papers

Discovery of Potent, Reversible, and Competitive Cruzain Inhibitors with Trypanocidal Activity: A Structure-Based Drug Design Approach

A virtual screening conducted with nearly 4?000?000 compounds from lead-like and fragment-like subsets enabled the identification of a small-molecule inhibitor (1) of the Trypanosoma cruzi cruzain enzyme, a validated drug target for Chagas disease. Subsequent comprehensive structure-based drug design and structure-activity relationship studies led to the discovery of carbamoyl imidazoles as potent, reversible, and competitive cruzain inhibitors. The most potent carbamoyl imidazole inhibitor (45) exhibited high affinity with a Ki value of 20 nM, presenting both in vitro and in vivo activity against T. cruzi. Furthermore, the most promising compounds reduced parasite burden in vivo and showed no toxicity at a dose of 100 mg/kg. These carbamoyl imidazoles are structurally attractive, nonpeptidic, and easy to prepare and synthetically modify. Finally, these results further advance our understanding of the noncovalent mode of inhibition of this pharmaceutically relevant enzyme, building strong foundations for drug discovery efforts.

Inhibitors of CYP 17

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q, and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

1, 3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS INHIBITORS OF CYP 17

The present invention provides compounds of Formula (I) and (II), or a pharmaceutically acceptable salts thereof, where R53, R54, p, q and n are as defined herein. The compounds of the present invention have been found to be useful as 17α-hydroxylase/C17,20-lyase inhibitors.

Mild, convenient and versatile Cu-mediated synthesis of N-aryl-2-imidazolidinones

A mild, general, convenient and practical methodology for the selective copper-mediated mono N-arylation of unprotected 2-imidazolidinone was developed. Strong electron-donating groups and free hydroxy and amino groups on the aryl iodide substrates were well tolerated. The use of n-butanol as the solvent for the copper-catalysed mono-arylation of 2-imidazolidinone is unprecedented.

Preparation of N-substituted imidazolidinones and N-substituted 2-thionimidazolidinones

The invention is a process for the preparation of N-substituted imidazolidinones and N-substituted 2-thionimidazolidinones which comprises contacting an oxazolidinone with a compound containing a nitrogen directly bonded to a carbonyl or a thiocarbonyl group in the presence of a Lewis acid catalyst or the hydrate of a Lewis acid catalyst under conditions such that an N-substituted imidazolidinone or N-substituted 2-thionimidazolidinone is prepared. The compound containing a nitrogen directly bonded to a carbonyl or a thiocarbonyl group is an isocyanate or isothiocyanate or a compound wherein the nitrogen is reactive and the carbonyl or thiocarbonyl group is further bonded to a substituent by a bond which is clevable under the reaction conditions. The Lewis acid catalyst corresponds to the formula wherein M is a group IB-VIIIB, IIIA or IVA element with the proviso that M is not C or Si; X is a halogen; and n is 2, 3 or 4.